Alteration of DSS-mediated immune cell redistribution in murine colitis by oral colostral immunoglobulin
© Bodammer et al; licensee BioMed Central Ltd. 2013
Received: 6 September 2012
Accepted: 1 February 2013
Published: 20 February 2013
Oral bovine colostrum prophylaxis accelerates the recovery of dextran sulfate sodium (DSS)-induced colitis. In the present study the beneficial effects on acute intestinal inflammation of two major colostral components, secretory immunoglobulin A and lactoferrin, were investigated. Outbred NMRI mice received whole bovine colostrum (BC, 20 mg/kg body weight), colostral bovine lactoferrin (bLf, 150 mg/kg), or secretory immunoglobulin A (sIgA, 1–2 mg/kg body weight) daily by oral gavage, either two weeks before induction of colitis (prophylaxis) or after disease establishment (therapy). Bovine serum albumin (BSA, 150 mg/kg body weight) and immunoglobulin G (IgG, 1 and 2 mg/kg body weight) served as protein controls. Colitis was induced by providing 5% DSS solution ad libitum for seven days.
Compared to BSA, BC therapy improved occult blood, stool consistency, and clinical recovery from colitis but did not prevent initial weight loss. In contrast, administration of bLf did not influence the course of colitis in either the prophylactic or the therapeutic setting. Therapeutic application of sIgA promoted weight gain in the recovery phase of colitis but failed to improve other clinical parameters. Prophylactically-fed sIgA influenced immune cell redistribution, normalized peripheral blood CD11c+CD83+ mature dendritic cells, modulated colonic immune cell infiltration, and altered the numbers of both DSS-induced regulatory γδ TCR+ T cells and CD11b+Gr-1+ myeloid suppressor cells in the lymph nodes and spleens of mice.
These data demonstrated the potential of colostrum in disease recovery and epithelial homeostasis following intestinal injury. Colostral sIgA failed to improve acute disease activity but promoted weight gain and modulated immune cell responses that are involved in the genesis of colitis.
KeywordsDSS-colitis Recovery Colostrum Secretory immunoglobulin A Bovine lactoferrin γδ- T-cells Myeloid-derived suppressor cells Outbred NMRI mice
Crohn’s disease and ulcerative colitis are chronic inflammatory disorders of the gut that cause major life-long disability. Afflicting mostly young people at an age when they are most active both in their private and professional life, inflammatory bowel disease (IBD) represents an important public health problem affecting the patients education, working abilities, social life and quality of life. The cause of IBD is multiple and so far not completely understood. However, genetic factors, environmental factors and the gut bacteria play a role in disease development.
Conventional therapy of active IBD pre-dominantly target anti-inflammatory immune responses, largely due to cytokine release within the intestine. Thus, therapeutic treatment mainly includes anti-inflammatory drugs, immunosuppressants, biologic agents, and antibiotics . However, these agents may cause severe adverse effects and are therefore not suitable for long-term treatment of IBD. Moreover, conventional drugs block manifestation or consequences of inflammation in acute disease. Thus, there is a necessity for therapeutic strategies that target improvement of impaired barrier function in remission. Suitable candidates are dietary supplements and food components such as colostrum. Although natural therapies are commonly associated with lower toxicity and fewer side effects than conventional drugs, the scientific proof of their effectiveness and safety is demanded .
Colostrum, the secretion produced by the mammary glands during the first three days post-partum, contains many functional nutrients. These include immunoglobulins, growth factors, and antimicrobial peptides. The potential of colostrum to affect gastrointestinal infections and to reduce the incidence of immune-mediated diseases is well established [3, 4]. In accordance with this, we recently demonstrated the protective effect of orally applied colostrum in a murine colitis model . Beneficial effects were characterized by improvement of clinical colorectal inflammation symptoms and by the induction of immunoregulatory mechanisms, predominantly of the innate immune system arm. Thus, identification of factors responsible for preventing experimental colitis might provide the basis for developing a long-term treatment regimen.
In IBD patients, local production of polymeric IgA (pIgA) is altered and this affects both immunological homeostasis and humoral immune responses [6, 7]. IgA does not activate the classical complement pathway and inhibits the production of pro-inflammatory cytokines in response to lipopolysaccharide (LPS), thereby maintaining mucosal integrity . SIgA preparations from colostrum are active against various microbial antigens and inhibit adhesion and invasion by enteropathogenic Escherichia coli in vitro[9, 10]. Colostral sIgA influences the development of the gastrointestinal immune system in milk-fed infants; however, little is known about the effectiveness of oral sIgA in maintaining gut barrier functions in adults.
Another colostral peptide with a broad range of immunomodulatory properties is lactoferrin (Lf), a member of the iron-binding glycoprotein family. Lf is predominately found in mucosal secretions and neutrophilic granules . Lf concentration and iron saturation differ among species; bovine (bLf) and human (hLf) Lfs show strong sequence homology . BLf has been reported to stimulate mucosal and systemic immune responses when given orally [13, 14]. Moreover, there is experimental evidence that Lf reduces the severity of colitis in rodents [15, 16].
In the present study, we explored the potential of orally applied colostral bLf and sIgA for modulating immune responses and recovery from dextran sodium sulfate (DSS)-induced murine colitis. Whole bovine colostrum (BC) improved the clinical severity of colitis, whereas bLf had no effect. SIgA influenced DSS-mediated immune cell redistribution and specifically altered colonic cell infiltration. Therefore, it might be an interesting candidate for promoting regeneration from acute colitis.
Therapeutic application of colostrum and sIgA improved clinical recovery from colitis
During the recovery phase, mice receiving therapeutic sIgA gained more weight than controls receiving NaCl (P = 0.077) or BSA (P = 0.002). BC and bLf showed only marginal differences from the control groups (NaCl, IgG, BSA). Since BSA-fed mice showed the most dramatic weight loss, up to 20% at day 14, the BC- and sIgA-induced recovery was not simply attributable to a feeding effect (Figure 1B).
Therapeutic application of colostrum or colostral components had no effect on histopathological severity of colitis
In contrast to the clinical benefit, BC and sIgA did not reduce colon shortening at day 15 after DSS challenge. In all experimental groups, colon lengths were significantly lower than those in controls not treated with DSS (see Additional file 1). Histological examination of the colon at day 15 revealed no significant differences in total histological score or in grade and extent of inflammation (see Additional file 1).
Therapeutic application of sIgA affected immune cell redistribution
Effect of prophylactically applied secretory IgA on clinical severity of colitis
Prophylactic application of secretory IgA failed to improve histopathological changes of colitis but affected colonic cell infiltration
Prophylactically applied secretory IgA normalized DSS-mediated redistribution of immune cells
Comparable though less pronounced effects were observed for splenic γδ TCR+ cells (Figure 5B). In mesenteric lymph nodes, a similar modulation of immune cell distribution was found. Here again, levels of mature CD11c+CD83+ dendritic cells were specifically normalized by sIgA prophylaxis (Figure 5C). Taken together, these data clearly pointed to immunological alterations by sIgA prophylaxis that influenced colonic inflammation.
Prophylactically applied secretory IgA increased levels of DSS-induced myeloid-derived suppressor cells
As shown in a previous study, oral BC prophylaxis accelerates recovery from DSS-induced colitis . However, most treatment regimens for IBD patients are not available before the onset of disease. Therefore, the present study was undertaken to evaluate the potential of whole BC and selected colostral compounds such as sIgA and bLf in a therapeutic setting. Both compounds display immunomodulatory potential [6, 11], are resistant against proteolytic degradation, and accumulate in blood and intestinal tissue of mice [18, 19].
The major finding of the study was that whole BC and in part colostral sIgA improved clinical recovery from colitis when applied therapeutically. This conclusion was confirmed by the enhanced weight gain of sIgA-fed mice and the lower disease activity (occult blood, diarrhea) in the BC-fed treatment group. Although BC and sIgA prevented neither the initial weight loss after induction of colitis nor the histological outcome of colitis, sIgA- and BC-fed mice recovered more quickly than control animals. In striking contrast, bLf failed to improve the clinical and histological course of colitis after both therapeutic and prophylactic applications (data not shown). This was surprising since bLf showed anti-inflammatory potential in DSS-induced colitis and stimulated mucosal and systemic immune responses when given orally [13, 14]. In addition, reduced LPS-induced epithelial damage and barrier destruction have been reported , as well as decreased rectal bleeding and an improved histological score . These findings, seemingly contradictory to our study, could be attributed to the fact that in these studies, human Lf with 7% iron saturation level was applied perorally twice a day. In contrast, we used Lf derived from bovine colostrum, and the level of iron saturation of bovine Lf was in range of 5 to 30%. Therefore, the discrepancy might be due to the therapeutic regimen rather than to the iron saturation level. Thus, increasing the number of Lf injections per day might have beneficial effects on the course of colitis. However, this was beyond the scope of the present study.
Another remarkable finding of our study was the effect of immunoglobulins on those immunological effector cells that most probably promote disease recovery. Mature DCs (CD11c+CD83+) and immunoregulatory γδ TCR+ T cells were almost normalized in lymph nodes and spleens in the sIgA and IgG groups. Similar data were obtained in the prophylactic setting. SIgA almost normalized the DSS-mediated cell redistribution (CD4+ T helper cells, γδ TCR+ T cells, CD11c+CD83+ mature dendritic cells) in lymph nodes and spleen.
Although γδ T cells are important in intestinal inflammation, the functional role of this cell population remains unknown. Under physiological conditions, they represent a minor subset within lymph nodes and spleens; however, they are induced in mice and men by inflammatory responses [21, 22]. Peripheral human γδ T cells exert regulatory functions and suppress T helper cell proliferation . Thus, the specific effects of sIgA on immune cell distribution can be regarded as favorable immune modulation of DSS-induced inflammation. In addition, colostral sIgA but not IgG influenced colonic cell infiltration. Just as whole BC is effective in preventing DSS-induced colitis, so sIgA treatment was characterized by massive increases in colonic CD11c+ and CD83+ DCs as well as γδ TCR+ T cells. Thus, the increase of local regulatory cells after BC prophylaxis was most likely to have been due to colostral sIgA rather than IgG. Activated γδ T cells have been shown to promote epithelial cell growth via the production of keratinocyte growth factor  and to regulate intestinal homeostasis , while depletion of γδ T cells worsened inflammation in mouse models of colitis [26, 27]. Therefore, in accordance with these studies, the enhanced recovery from colitis was most probably mediated by immune cell modulation through colostrum and in particular colostral sIgA.
In our previous study, we hypothesized that MDSCs contributed to the clinical benefit of prophylactically applied colostrum . Here again, sIgA prophylaxis specifically increased the number of splenic CD11b+Gr-1+ MDSCs. Although the function of CD11b+Gr-1+ MDSC in intestinal inflammation remains unclear, MDSCs accumulated in the bone marrow and spleen of DSS-exposed mice, and intravenous transplantation of DSS-induced splenic CD11b+Gr-1+ cells in C57Bl/6 mice resulted in advanced mucosal healing . We therefore conclude that the strong induction of CD11b+Gr-1+ cells by sIgA contributed to the enhanced recovery from weight loss at later time points.
In conclusion, we tested the immunomodulatory potential of sIgA and bLf for improving the severity of DSS-induced murine colitis. SIgA but not bLf was identified as a colostral component that altered immune responses and promoted weight gain in colitic mice. Further studies are required to explore how this natural colostral compound modulates the colitis-induced immune cell redistribution.
Female outbred NMRI mice were purchased from Harlan Winkelmann GmbH (Melderslo, Netherlands) at the age of four to six months. They received standard food and water ad libitum. Mice aged eight to twelve months (average body weight 30 g) were randomly assigned to different experimental groups. All animal experiments were performed in compliance with the German animal protection law (TierSchG BGBI S. 1105; 25.05.1998) and were approved by the local commitee on the ethics of animal experiments of the University of Rostock (Landesamt für Landwirtschaft, Lebensmittelsicherheit und Fischerei Mecklenburg-Vorpommern) under permit number 2007/06/14;LALLFM-V/TSD/7221.3-1.1-059/08.
Colostrum, lactoferrin and secretory immunoglobulin a
For the therapeutic setting, BC powder (SANIMALIS, Heinsberg, Germany) was skimmed, pasteurized, and freeze-dried to ensure minimum denaturation of immunoglobulins and nutrients. The total protein content of the colostrum preparation was 60–70 g/100 g.
The BC (SANIMALIS) solution used for prophylactic treatment was skimmed, casein-free and sterile-filtered. The concentrations of immunoglobulin and other major ingredients were as previously described . The total protein content was 7.25 g/100 ml (carbohydrate 0.2 g/100 ml, fat < 0.01 g/100 ml).
BLf was purified from bovine, and sIgA from human colostrum. IgG was isolated from human serum. All therapeutic agents were purchased from Sigma-Aldrich (Taufkirchen, Germany). Bovine BSA (Sigma-Aldrich) served as control.
Induction of colitis
Acute colitis was induced by DSS, as previously described . Briefly, DSS (36–50 kDa; MP Biomedicals, Eschwege, Germany) was dissolved in sterilized tap water and presented to the mice at a final concentration of 5% for seven days. Fresh DSS solution was provided every second day.
Therapeutic treatment protocol
All therapeutic interventions were initiated from day 3 after starting DSS exposure until the end of the experiment (day 15). Either 20 mg/kg bw BC powder (BC, n = 6), 1 mg/kg bw sIgA (sIgA, n = 6), IgG (IgG, n = 6), 150 mg/kg bw bLf (bLf, n = 5) or protein control (BSA, n = 5) were dissolved in physiological sodium chloride solution (0.9% NaCl) and given to each mouse in a final volume of 100 μl daily by oral gavage. DSS-treated negative controls received 100 μl NaCl (DSS, n = 8). Physiological values were obtained from animals with no intervention (untreated, n = 6-8).
Prophylactic treatment protocol
One hundred μl of pure BC (n = 6) was given to the mice orally by gavage daily for 14 days. All prophylactic treatments were initiated two weeks prior to colitis induction. SIgA and IgG were dissolved in NaCl. Each mouse received 2 mg/kg bw sIgA (n = 8) or IgG (n = 8) in final volume of 100 μl daily for 14 days by oral gavage.
Clinical evaluation of colitis
After starting DSS exposure at day 1, the mice were weighed daily until the end of the experiment at day 15. Weight loss during the induction phase of colitis was observed from day 1 to day 7 (day 1 = 100%), whereas the recovery phase was defined as weight gain after stopping DSS until the end of the experiment from day 8 to day 14 (day 8 = 100%). Stool consistency was checked for diarrhea and feces were screened for blood during the acute inflammation phase of colitis from day 1 to day 7 (therapeutic protocol) or from day 1 to day 14 (prophylactic protocol) using a HemoCARE occult blood detection kit (Care Diagnostica, Voerde, Germany). DAI was determined according to Cooper et al. (1993) with minor modifications, by scoring changes in fecal blood, and stool consistency, as shown in Additional file 3.
Mice were killed on day 15 after starting DSS. At autopsy, whole colons were removed and their lengths were measured. The colons were unrolled and divided longitudinally into two parts. One part was fixed and embedded in paraffin. Sections were stained with hematoxylin and eosin. The degree of colonic inflammation was analyzed by a pathologist in a blinded fashion, according to the scoring system originally described by Cooper et al. (1993) as shown in Additional file 4.
Flow cytometry was performed on leukocytes from peripheral blood, spleens, and mesenteric lymph nodes as described previously . Briefly, leukocytes were labeled using the following fluorescein isothiocyanate (FITC)- and phycoerythrin (PE)-conjugated anti-mouse monoclonal antibodies (mAbs) at the appropriate concentrations: CD3ε FITC, CD19 FITC, γδ TCR PE (ImmunoTools, Fiesoythe, Germany), CD11b FITC, CD11c FITC, CD4 PE, CD8 PE; Gr-1 PE (Miltenyi Biotech, Bergisch-Gladbach, Germany), CD83 PE (eBioscience, Frankfurt, Germany). Negative controls consisted of lymphocytes stained with the appropriate isotype controls. Myeloid-derived suppressor cells (MDSC) were defined as CD11b+Gr-1+. Subsets of these cell populations were detected by gating on the CD11b+Gr-1+high, CD11b+Gr-1+intermediate, or CD11b+Gr-1+low fraction, definable by varying expression intensity. Samples were analyzed on a FACSCalibur Cytometer (BD Pharmingen) using CellQuest software and gating on total leukocytes (BD Biosciences, Mountain View, CA USA). Relative numbers are given.
Values are reported as the mean ± standard deviation (SD). To ensure reproducibility, experiments were repeated twice with three to four mice per group (except therapeutic experiment group DSS + bLf and DSS + BSA). Data from separate experiments were combined for statistical analysis and presentation in figures and tables. Owing to small sample sizes, group and time effects of clinical parameters (weight loss, DAI) were analyzed by a nonparametric one-way ANOVA model for repeated measurements using SAS 9.2 software . To analyze the impact of DSS-colitis on histological parameters (cell infiltration and distribution, colon length) we first compared between untreated and NaCl groups. To analyze the influence of the treatment during the course of colitis, comparison was made between NaCl and the susceptive treatment group (BC, sIgA, and bLf). For the impact of BC and sIgA, we used BSA as appropriate protein control. To analyze whether observed immunoglobulin-induced effects are specific for sIgA, we used IgG as control. Analyses were performed with the parameter-free Mann Whitney U-test using SPSS software . P < 0.05 was considered the criterion for statistical significance.
Bovine Serum Albumin
Complementary and Alternative Medicine
Disease Activity Index
Dextran Sulfate Sodium
Inflammatory Bowel Diseases
secretory Immunoglobulin A.
We thank the late Dr. Joerg Emmrich for his helpful conversations about this work. All of those who knew him will miss his collegiality and wise advice. We acknowledge Dr. Horst Nizze’s help with scoring the histological changes of DSS-exposed colons and Julia Glamann for her excellent technical assistance. This study was financially supported by the research grant for complementary medicine in IBD of the “Deutsche Crohn und Colitis Vereinigung”, DCCV e.V.
- Triantafillidis JK, Merikas E, Georgopoulos F: Current and emerging drugs for the treatment of inflammatory bowel disease. Drug Des Devel Ther. 2011, 5: 185-210.PubMed CentralView ArticlePubMedGoogle Scholar
- Langmead L, Rampton DS: Review article: complementary and alternative therapies for inflammatory bowel disease. Aliment Pharmacol Ther. 2006, 23: 341-349. 10.1111/j.1365-2036.2006.02761.x.View ArticlePubMedGoogle Scholar
- Playford RJ, Macdonald CE, Johnson WS: Colostrum and milk-derived peptide growth factors for the treatment of gastrointestinal disorders. Am J Clin Nutr. 2000, 72: 5-14.PubMedGoogle Scholar
- Solomons NW: Modulation of the immune system and the response against pathogens with bovine colostrum concentrates. Eur J Clin Nutr. 2002, 56 (Suppl 3): 24-28.View ArticleGoogle Scholar
- Bodammer P, Maletzki C, Waitz G, Emmrich J: Prophylactic application of bovine colostrum ameliorates murine colitis via induction of immunoregulatory cells. J Nutr. 2011, 141: 1056-1061. 10.3945/jn.110.128702.View ArticlePubMedGoogle Scholar
- Brandtzaeg P, Carlsen HS, Halstensen TS: The B-cell system in inflammatory bowel disease. Adv Exp Med Biol. 2006, 579: 149-167. 10.1007/0-387-33778-4_10.View ArticlePubMedGoogle Scholar
- Thoree VC, Golby SJ, Boursier L, Hackett M, Dunn-Walters DK, Sanderson JD, Spencer J: Related IgA1 and IgG producing cells in blood and diseased mucosa in ulcerative colitis. Gut. 2002, 51: 44-50. 10.1136/gut.51.1.44.PubMed CentralView ArticlePubMedGoogle Scholar
- Murthy AK, Dubose CN, Banas JA, Coalson JJ, Arulanandam BP: Contribution of polymeric immunoglobulin receptor to regulation of intestinal inflammation in dextran sulfate sodium-induced colitis. J Gastroenterol Hepatol. 2006, 21: 1372-1380.PubMedGoogle Scholar
- Carbonare CB, Carbonare SB, Carneiro-Sampaio MM: Secretory immunoglobulin a obtained from pooled human colostrum and milk for oral passive immunization. Pediatr Allergy Immunol. 2005, 16: 574-581. 10.1111/j.1399-3038.2005.00332.x.View ArticlePubMedGoogle Scholar
- Sawai T, Goldstone N, Drongowski RA, Coran AG, Harmon CM: Effect of secretory immunoglobulin a on bacterial translocation in an enterocyte-lymphocyte co-culture model. Pediatr Surg Int. 2001, 17: 275-279. 10.1007/s003830100593.View ArticlePubMedGoogle Scholar
- Actor JK, Hwang SA, Kruzel ML: Lactoferrin as a natural immune modulator. Curr Pharm Des. 2009, 15: 1956-1973. 10.2174/138161209788453202.PubMed CentralView ArticlePubMedGoogle Scholar
- Buccigrossi V, de Marco G, Bruzzese E, Ombrato L, Bracale I, Polito G, Guarino A: Lactoferrin induces concentration-dependent functional modulation of intestinal proliferation and differentiation. Pediatr Res. 2007, 61: 410-414. 10.1203/pdr.0b013e3180332c8d.View ArticlePubMedGoogle Scholar
- Debbabi H, Dubarry M, Rautureau M, Tomé D: Bovine lactoferrin induces both mucosal and systemic immune response in mice. J Dairy Res. 1998, 65: 283-293. 10.1017/S0022029997002732.View ArticlePubMedGoogle Scholar
- Sfeir RM, Dubarry M, Boyaka PN, Rautureau M, Tomé D: The mode of oral bovine lactoferrin administration influences mucosal and systemic immune responses in mice. J Nutr. 2004, 134: 403-409.PubMedGoogle Scholar
- Håversen LA, Baltzer L, Dolphin G, Hanson LA, Mattsby-Baltzer I: Anti-inflammatory activities of human lactoferrin in acute dextran sulphate-induced colitis in mice. Scand J Immunol. 2003, 57: 2-10. 10.1046/j.1365-3083.2003.01162.x.View ArticlePubMedGoogle Scholar
- Togawa J, Nagase H, Tanaka K, Inamori M, Nakajima A, Ueno N, Saito T, Sekihara H: Oral administration of lactoferrin reduces colitis in rats via modulation of the immune system and correction of cytokine imbalance. J Gastroenterol Hepatol. 2002, 17: 1291-10.1046/j.1440-1746.2002.02868.x.View ArticlePubMedGoogle Scholar
- Zhang R, Ito S, Nishio N, Cheng Z, Suzuki H, Isobe KI: Dextran sulphate sodium increases splenic Gr1(+)CD11b(+) cells which accelerate recovery from colitis following intravenous transplantation. Clin Exp Immunol. 2011, 164: 417-427. 10.1111/j.1365-2249.2011.04374.x.PubMed CentralView ArticlePubMedGoogle Scholar
- Fischer R, Debbabi H, Blais A, Dubarry M, Rautureau M, Boyaka PN, Tome D: Uptake of ingested bovine lactoferrin and its accumulation in adult mouse tissues. Int Immunopharmacol. 2007, 10: 1387-1393.View ArticleGoogle Scholar
- Warny M, Fatimi A, Bostwick EF, Laine DC, Lebel F, LaMont JT, Pothoulakis C, Kelly CP: Bovine immunoglobulin concentrate-clostridium difficile retains C difficile toxin neutralising activity after passage through the human stomach and small intestine. Gut. 1999, 44: 212-217. 10.1136/gut.44.2.212.PubMed CentralView ArticlePubMedGoogle Scholar
- Hirotani Y, Ikeda K, Kato R, Myotoku M, Umeda T, Ijiri Y, Tanaka K: Protective effects of lactoferrin against intestinal mucosal damage induced by lipopolysaccharide in human intestinal caco-2 cells. Yakugaku Zasshi. 2008, 128: 1363-1368. 10.1248/yakushi.128.1363.View ArticlePubMedGoogle Scholar
- Tsuchiya T, Fukuda S, Hamada H, Nakamura A, Kohama Y, Ishikawa H, Tsujikawa K, Yamamoto H: Role of gamma delta T cells in the inflammatory response of experimental colitis mice. J Immunol. 2003, 171: 5507-5513.View ArticlePubMedGoogle Scholar
- Giacomelli R, Parzanese I, Frieri G, Passacantando A, Pizzuto F, Pimpo T, Cipriani P, Viscido A, Caprilli R, Tonietti G: Increase of circulating gamma/delta T lymphocytes in the peripheral blood of patients affected by active inflammatory bowel disease. Clin Exp Immunol. 1994, 98: 83-88.PubMed CentralView ArticlePubMedGoogle Scholar
- Kühl AA, Pawlowski NN, Grollich K, Blessenohl M, Westermann J, Zeitz M, Loddenkemper C, Hoffmann JC: Human peripheral gammadelta T cells possess regulatory potential. Immunology. 2009, 128: 580-588. 10.1111/j.1365-2567.2009.03162.x.PubMed CentralView ArticlePubMedGoogle Scholar
- Boismenu R, Havran WL: Modulation of epithelial cell growth by intraepithelial gamma delta T cells. Science. 1994, 266: 1253-1255. 10.1126/science.7973709.View ArticlePubMedGoogle Scholar
- Komano H, Fujiura Y, Kawaguchi M, Matsumoto S, Hashimoto Y, Obana S, Mombaerts P, Tonegawa S, Yamamoto H, Itohara S, Nannot M, Ishikawat H: Homeostatic regulation of intestinal epithelia by intraepithelial gamma delta T cells. Proc Natl Acad Sci. 1995, 92: 6147-6151. 10.1073/pnas.92.13.6147.PubMed CentralView ArticlePubMedGoogle Scholar
- Kühl AA, Loddenkemper C, Westermann J, Hoffmann JC: Role of gamma delta T cells in inflammatory bowel disease. Pathobiology. 2002–2003, 70: 150-155. 10.1159/000068147.View ArticleGoogle Scholar
- Kühl AA, Pawlowski NN, Grollich K, Loddenkemper C, Zeitz M, Hoffmann JC: Aggravation of intestinal inflammation by depletion/deficiency of gammadelta T cells in different types of IBD animal models. J Leukoc Biol. 2007, 81: 168-175.View ArticlePubMedGoogle Scholar
- Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R: A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology. 1990, 98: 694-702.PubMedGoogle Scholar
- Cooper HS, Murthy SN, Shah RS, Sedergran DJ: Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest. 1993, 69: 238-249.PubMedGoogle Scholar
- Brunner E, Domhof S, Langer F: Nonparametric analysis of longitudinal data in factorial experiments. 2002, In Probability and Statistics. New York: John Wiley & SonsGoogle Scholar
- Mann HB, Whitney DR: On a test of whether one of Two random variables is stochastically larger than the other. Annals Math Stats. 1947, 18: 50-60. 10.1214/aoms/1177730491.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.